TLK-286

Claire F. Verschraegen, Harriet O. Smith, Fa Chyi Lee, Cynthia Cathcart, Jeffery P. Norenberg

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Telik Inc is developing TLK-286, a modified glutathione analog prodrug, for the potential treatment of cancer.

Original languageEnglish (US)
Pages (from-to)771-781
Number of pages11
JournalIDrugs
Volume7
Issue number8
StatePublished - Aug 1 2004

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'TLK-286'. Together they form a unique fingerprint.

Cite this